Literature DB >> 15470485

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.

M C Minnema, I Breitkreutz, J J A Auwerda, B van der Holt, F W Cremer, A M W van Marion, P H M Westveer, P Sonneveld, H Goldschmidt, H M Lokhorst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15470485     DOI： 10.1038/sj.leu.2403533

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis.

Authors:  J C Easaw; M A Shea-Budgell; C M J Wu; P M Czaykowski; J Kassis; B Kuehl; H J Lim; M MacNeil; D Martinusen; P A McFarlane; E Meek; O Moodley; S Shivakumar; V Tagalakis; S Welch; P Kavan
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

2.  Coarse-grained molecular dynamics simulations of fibrin polymerization: effects of thrombin concentration on fibrin clot structure.

Authors:  Sumith Yesudasan; Xianqiao Wang; Rodney D Averett
Journal:  J Mol Model       Date:  2018-04-05       Impact factor: 1.810

3.  Fibrin polymerization simulation using a reactive dissipative particle dynamics method.

Authors:  Sumith Yesudasan; Xianqiao Wang; Rodney D Averett
Journal:  Biomech Model Mechanobiol       Date:  2018-05-23

4.  Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.

Authors:  Minjie Gao; Yuanyuan Kong; Houcai Wang; Bingqian Xie; Guang Yang; Lu Gao; Yiwen Zhang; Fenghuang Zhan; Bojie Dai; Yi Tao; Jumei Shi
Journal:  Tumour Biol       Date:  2016-02-23

5.  A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.

Authors:  Camilo E Fadul; Linda S Kingman; Louise P Meyer; Bernard F Cole; Clifford J Eskey; C Harker Rhodes; David W Roberts; Herbert B Newton; J Marc Pipas
Journal:  J Neurooncol       Date:  2008-07-26       Impact factor: 4.130

6.  Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma.

Authors:  Jae-Cheol Jo; Byung Woog Kang; Sun Jin Sym; Sung Sook Lee; Geundoo Jang; Shin Kim; Dae Ho Lee; Sang-We Kim; Jung Shin Lee; Cheolwon Suh
Journal:  Invest New Drugs       Date:  2009-10-13       Impact factor: 3.850

7.  Evidence-based guidance on venous thromboembolism in patients with solid tumours.

Authors:  M A Shea-Budgell; C M J Wu; J C Easaw
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

Review 8.  Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Authors:  Marcello Di Nisio; Ettore Porreca; Matteo Candeloro; Michele De Tursi; Ilaria Russi; Anne Ws Rutjes
Journal:  Cochrane Database Syst Rev       Date:  2016-12-01

9.  Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Authors:  Anne Ws Rutjes; Ettore Porreca; Matteo Candeloro; Emanuele Valeriani; Marcello Di Nisio
Journal:  Cochrane Database Syst Rev       Date:  2020-12-18

Review 10.  Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents.

Authors:  Lara A Kahale; Charbel F Matar; Ibrahim Tsolakian; Maram B Hakoum; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Maddalena Barba; Lisa K Hicks; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2021-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.